CD274 and metastatic colorectal cancer: To further investigate the association of metastatic disease pattern with response to PD-1– or PD-L1–targeting therapy in MSS colorectal cancer, we performed a single-center retrospective analysis of all patients with treatment-resistant MSS metastatic colorectal cancer treated at City of Hope Comprehensive Cancer Center, Duarte, California, with PD-1 or PD-L1 inhibitors during the last 6 years.